| Drug General Information |
| Drug ID |
D03ZJE
|
| Former ID |
DNC001089
|
| Drug Name |
PAI-1
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 4 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H27NO4
|
| Canonical SMILES |
CCCCCCCCCC(=O)CC(=O)NC1CCOC1=O
|
| InChI |
1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)
|
| InChIKey |
PHSRRHGYXQCRPU-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14002, 10241879, 14873627, 29307045, 52169859, 57342355, 103640299, 104366800, 123058754, 125335308, 125569363, 128917720, 135082566, 142062025, 204364836, 223661376, 235415351
|
| Target and Pathway |
| Target(s) |
Urokinase-type plasminogen activator |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Complement and coagulation cascades
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
PANTHER Pathway
|
Blood coagulation
|
|
Plasminogen activating cascade
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Beta1 integrin cell surface interactions
|
|
E2F transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
Beta2 integrin cell surface interactions
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
FGF signaling pathway
|
|
Reactome
|
Dissolution of Fibrin Clot
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Complement and Coagulation Cascades
|
|
Endochondral Ossification
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Blood Clotting Cascade
|
|
Dissolution of Fibrin Clot
|
|
Osteopontin Signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00770328) The Effects of Pentoxifylline on PAI-1 in an Obese Population. U.S. National Institutes of Health. |
|---|
| REF 2 | Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6. |
|---|
